参考文献/References:
[1]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2018[J].CA Cancer J Clin,2018,68(1):7-30.[2]D’souza S,Addepalli V.Preventive measures in oral cancer: An overview[J].Biomed Pharmacother,2018,107:72-80.[3]Noguti J,De Moura CF,De Jesus GP,et al.Metastasis from oral cancer: an overview[J].Cancer Genomics Proteomics,2012,9(5):329-335.[4]van der Waal I.Are we able to reduce the mortality and morbidity of oral cancer; some considerations[J].Med Oral Patol Oral Cir Bucal,2013,18(1):e33-e37.[5]Dhamija S,Diederichs S.From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis[J].Int J Cancer,2016,139(2):269-280.[6]Peng WX,Koirala P,Mo YY.LncRNA-mediated regulation of cell signaling in cancer[J].Oncogene,2017,36(41):5661-5667.[7]Zhang S,Ma H,Zhang D,et al.LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling[J].Cell Death Dis,2018,9(7):742.[8]Chen S,Yang M,Wang C,et al.Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma[J].Cancer Lett,2021,503:43-53.[9]Momen-Heravi F,Bala S.Emerging role of non-coding RNA in oral cancer[J].Cell Signal,2018,42:134-143.[10]Zhou X,Liu S,Cai G,et al.Long Non Coding RNA MALAT1 Promotes Tumor Growth and Metastasis by inducing Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma[J].Sci Rep,2015,5:15972.[11]Lan Y,Liu B,Guo H.The role of M6A modification in the regulation of tumor-related lncRNAs[J].Mol Ther Nucleic Acids,2021,24:768-779.[12]Sun T,Wu R,Ming L.The role of m6A RNA methylation in cancer[J].Biomed Pharmacother,2019,112:108613.[13]Chi H,Zhao S,Yang J,et al.T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing[J].Front Immunol,2023,14:1137025.[14]Liu HT,Zou YX,Zhu WJ,et al.lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus[J].Cell Death Differ,2022,29(3):627-641.[15]Liu R,Yin G,Tuo H,et al.METTL3-induced lncRNA GBAP1 promotes hepatocellular carcinoma progression by activating BMP/SMAD pathway[J].Biol Direct,2023,18(1):53.[16]Bolha L,Ravnik-Glavac M,Glavac D.Long Noncoding RNAs as Biomarkers in Cancer[J].Dis Markers,2017,2017:7243968.[17]He L,Li H,Wu A,et al.Functions of N6-methyladenosine and its role in cancer[J].Mol Cancer,2019,18(1):176.[18]Zaccara S,Ries RJ,Jaffrey SR.Reading, writing and erasing mRNA methylation[J].Nat Rev Mol Cell Biol,2019,20(10):608-624.[19]Chong W,Shang L,Liu J,et al.m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer[J].Theranostics,2021,11(5):2201-2217.[20]Newman AM,Liu CL,Green MR,et al.Robust enumeration of cell subsets from tissue expression profiles[J].Nat Methods,2015,12(5):453-457.[21]Mayakonda A,Lin DC,Assenov Y,et al.Maftools: efficient and comprehensive analysis of somatic variants in cancer[J].Genome Res,2018,28(11):1747-1756.[22]Chen J,Lu T,Zhong F,et al.A Signature of N6-methyladenosine Regulator-Related Genes Predicts Prognoses and Immune Responses for Head and Neck Squamous Cell Carcinoma[J].Front Immunol,2022,13:809872.[23]Zhu W,Ye Z,Chen L,et al.A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma[J].Int Immunopharmacol,2021,101(Pt B):108268.[24]Zhong F,Liu S,Hu D,et al.LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis[J].J Cancer,2022,13(3):1048-1060.[25]Bao J,Wu Y,Zhang K,et al.AC099850.3/NCAPG Axis Predicts Poor Prognosis and is Associated with Resistance to EGFR Tyrosine-Kinase Inhibitors in Lung Adenocarcinoma[J].Int J Gen Med,2022,15:6917-6930.[26]Qiu L,Tao A,Liu F,et al.Potential prognostic value of a eight ferroptosis-related lncRNAs model and the correlative immune activity in oral squamous cell carcinoma[J].BMC Genom Data,2022,23(1):80.[27]Lu M,Zhan H,Liu B,et al.N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer[J].EPMA J,2021,12(4):589-604.[28]He Y,Hua R,Yang Y,et al.LncRNA JPX Promotes Esophageal Squamous Cell Carcinoma Progression by Targeting miR-516b-5p/VEGFA Axis[J].Cancers (Basel),2022,14(11):2713.[29]Yao Y,Chen S,Lu N,et al.LncRNA JPX overexpressed in oral squamous cell carcinoma drives malignancy via miR-944/CDH2 axis[J].Oral Dis,2021,27(4):924-933. [30]Sun D,Gou H,Wang D,et al.LncRNA TNFRSF10A-AS1 promotes gastric cancer by directly binding to oncogenic MPZL1 and is associated with patient outcome[J].Int J Biol Sci,2022,18(8):3156-3166.[31]Wang Y,Zhang D,Li Y,et al.Constructing a novel signature and predicting the immune landscape of colon cancer using N6-methylandenosine-related lncRNAs[J].Front Genet,2023,14:906346.[32]Nguyen QH,Nguyen T,Le DH.Identification and Validation of a Novel Three Hub Long Noncoding RNAs With m6A Modification Signature in Low-Grade Gliomas[J].Front Mol Biosci,2022,9:801931.[33]Chen Z,Yang F,Liu H,et al.Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia[J].Aging (Albany NY),2021,13(11):15548-15568.[34]Li W,Gao Y,Jin X,et al.Comprehensive analysis of N6-methylandenosine regulators and m6A-related RNAs as prognosis factors in colorectal cancer[J].Mol Ther Nucleic Acids,2021,27:598-610.[35]Chen YG,Satpathy AT,Chang HY.Gene regulation in the immune system by long noncoding RNAs[J].Nat Immunol,2017,18(9):962-972.[36]Atianand MK,Caffrey DR,Fitzgerald KA.Immunobiology of Long Noncoding RNAs[J].Annu Rev Immunol,2017,35:177-198.[37]Zhang Y,Li Z,Chen M,et al.lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer[J].Breast Cancer,2020,27(4):573-585.[38]Garon EB,Hellmann MD,Rizvi NA,et al.Five-Year Overall Survival for Patients With Advanced Non?Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study[J].J Clin Oncol,2019,37(28):2518-2527.[39]Sautès-Fridman C,Lawand M,Giraldo NA,et al.Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention[J].Front Immunol,2016,7:407.[40]Zhang Y,Guo J,Jia R.Treg: A Promising Immunotherapeutic Target in Oral Diseases[J].Front Immunol,2021,12:667862.[41]Galon J,Costes A,Sanchez-Cabo F,et al.Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J].Science,2006,313(5795):1960-1964.[42]Chan TA,Yarchoan M,Jaffee E,et al.Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic[J].Ann Oncol,2019,30(1):44-56.[43]Xu F,Jin T,Zhu Y,et al.Immune checkpoint therapy in liver cancer[J].J Exp Clin Cancer Res,2018,37(1):110.[44]Chen D,Barsoumian HB,Yang L,et al.SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer[J].Cancer Immunol Res,2020,8(7):883-894.[45]Wang J,Li J,Tang G,et al.Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma[J].Oncol Lett,2021,21(4):279.